A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19-Reference-Cited by-同舟云学术

A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19

Published:2023-06-15 Issue:3 Volume:11 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Miyazaki Taiga¹²^ORCID,Hosogaya Naoki³⁴,Fukushige Yuri³,Takemori Sachiko³,Morimoto Shinpei³,Yamamoto Hiroshi³,Hori Makoto⁵,Ozawa Yoshihito⁵,Shiko Yuki⁵,Inaba Yosuke⁵,Kurokawa Tomoya⁵,Hanaoka Hideki⁵,Iwanami Shoya⁶,Kim Kwangsu⁶,Iwami Shingo⁶,Watashi Koichi⁷,Miyazawa Ken⁸^ORCID,Umeyama Takashi⁸,Yamagoe Satoshi⁹,Miyazaki Yoshitsugu⁸^ORCID,Wakita Takaji¹⁰,Sumiyoshi Makoto¹,Hirayama Tatsuro⁴¹¹^ORCID,Izumikawa Koichi¹²,Yanagihara Katsunori¹³,Mukae Hiroshi⁴,Kawasuji Hitoshi¹⁴,Yamamoto Yoshihiro¹⁴,Tarumoto Norihito¹⁵,Ishii Hiroshi¹⁶,Ohno Hideaki¹⁷,Yatera Kazuhiro¹⁸,Kakeya Hiroshi¹⁹,Kichikawa Yoshiko²⁰,Kato Yasuyuki²¹,Matsumoto Tetsuya²¹,Saito Makoto²²^ORCID,Yotsuyanagi Hiroshi²²,Kohno Shigeru²

Affiliation:

1. Division of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

2. Nagasaki University, Nagasaki, Japan

3. Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan

4. Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan

5. Division of Clinical Research Center, Chiba University Hospital, Chiba, Japan

6. interdisciplinary Biology Laboratory (iBLab), Division of Biological Sciences, Graduate School of Science, Nagoya University, Aichi, Japan

7. Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan

8. Department of Fungal Infection, National Institute of Infectious Diseases, Tokyo, Japan

9. Section of Infectious Resource Coordination, Department of Research Resource, Center of Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan

10. National Institute of Infectious Diseases, Tokyo, Japan

11. Department of Pharmacotherapeutics, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan

12. Infection Control and Education Center, Nagasaki University Hospital, Nagasaki, Japan

13. Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan

14. Department of Infectious Disease, Toyama University Hospital, Toyama, Japan

15. Department of Infectious Disease and Infection Control, Saitama Medical University Hospital, Saitama, Japan

16. Department of Respiratory Medicine, Fukuoka University Chikushi Hospital, Fukuoka, Japan

17. Department of Infectious Disease and Infection Control, Saitama Medical Center, Saitama, Japan

18. Department of Respiratory Medicine, Hospital of the University of Occupational and Environmental Health, Japan, Fukuoka, Japan

19. Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan

20. Division of Respiratory Medicine, Mishuku Hospital, Tokyo, Japan

21. Department of Infectious Diseases, International University of Health and Welfare Narita Hospital, Chiba, Japan

22. Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Abstract

The anti-HIV drug nelfinavir suppresses the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro . However, its efficacy in patients with COVID-19 has not been studied.

Funder

Japan Agency for Medical Research and Development

Ministry of Health, Labour and Welfare

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.04311-22

Reference30 articles.

1. World Health Organization. 2020. Novel coronavirus (2019-nCoV): situation report vol 1. https://apps.who.int/iris/handle/10665/330760. Accessed 11 April 2022.

2. United States National Institutes of Health. Coronavirus Disease. 2019. 2019 (COVID-19) treatment guidelines. https://www.covid19treatmentguidelines.nih.gov. Accessed 11 April 2022.

3. Food and Drug Administration. 2022. Fact sheet for healthcare providers: emergency use authorization for Paxlovid. https://www.fda.gov/media/155050/download.

4. Food and Drug Administration. 2021. Fact sheet for healthcare providers: emergency use authorization for Lagevrio (molnupiravir) capsules. https://www.fda.gov/media/155054/download.

5. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms